CDTX
Price
$63.89
Change
+$0.46 (+0.73%)
Updated
Sep 4, 01:57 PM (EDT)
Capitalization
1.61B
ICCC
Price
$6.66
Change
+$0.13 (+1.99%)
Updated
Sep 4, 01:48 PM (EDT)
Capitalization
59.03M
74 days until earnings call
Interact to see
Advertisement

CDTX vs ICCC

Header iconCDTX vs ICCC Comparison
Open Charts CDTX vs ICCCBanner chart's image
Cidara Therapeutics
Price$63.89
Change+$0.46 (+0.73%)
Volume$300
Capitalization1.61B
ImmuCell
Price$6.66
Change+$0.13 (+1.99%)
Volume$100
Capitalization59.03M
CDTX vs ICCC Comparison Chart in %
Loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDTX vs. ICCC commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDTX is a Hold and ICCC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (CDTX: $63.43 vs. ICCC: $6.53)
Brand notoriety: CDTX and ICCC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDTX: 34% vs. ICCC: 33%
Market capitalization -- CDTX: $1.61B vs. ICCC: $59.03M
CDTX [@Biotechnology] is valued at $1.61B. ICCC’s [@Biotechnology] market capitalization is $59.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDTX’s FA Score shows that 0 FA rating(s) are green whileICCC’s FA Score has 0 green FA rating(s).

  • CDTX’s FA Score: 0 green, 5 red.
  • ICCC’s FA Score: 0 green, 5 red.
According to our system of comparison, ICCC is a better buy in the long-term than CDTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDTX’s TA Score shows that 3 TA indicator(s) are bullish while ICCC’s TA Score has 6 bullish TA indicator(s).

  • CDTX’s TA Score: 3 bullish, 4 bearish.
  • ICCC’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, ICCC is a better buy in the short-term than CDTX.

Price Growth

CDTX (@Biotechnology) experienced а -3.00% price change this week, while ICCC (@Biotechnology) price change was +6.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.71%. For the same industry, the average monthly price growth was +5.90%, and the average quarterly price growth was +27.78%.

Reported Earning Dates

ICCC is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (-0.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDTX($1.61B) has a higher market cap than ICCC($59M). CDTX YTD gains are higher at: 135.975 vs. ICCC (26.718). ICCC has higher annual earnings (EBITDA): 4.96M vs. CDTX (-208.92M). CDTX has more cash in the bank: 511M vs. ICCC (6M). CDTX has less debt than ICCC: CDTX (2.33M) vs ICCC (14.3M). ICCC has higher revenues than CDTX: ICCC (28.3M) vs CDTX (0).
CDTXICCCCDTX / ICCC
Capitalization1.61B59M2,725%
EBITDA-208.92M4.96M-4,215%
Gain YTD135.97526.718509%
P/E RatioN/A31.08-
Revenue028.3M-
Total Cash511M6M8,520%
Total Debt2.33M14.3M16%
FUNDAMENTALS RATINGS
CDTX vs ICCC: Fundamental Ratings
CDTX
ICCC
OUTLOOK RATING
1..100
735
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
10089
SMR RATING
1..100
9779
PRICE GROWTH RATING
1..100
3447
P/E GROWTH RATING
1..100
10039
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ICCC's Valuation (78) in the Medical Specialties industry is in the same range as CDTX (85) in the Biotechnology industry. This means that ICCC’s stock grew similarly to CDTX’s over the last 12 months.

ICCC's Profit vs Risk Rating (89) in the Medical Specialties industry is in the same range as CDTX (100) in the Biotechnology industry. This means that ICCC’s stock grew similarly to CDTX’s over the last 12 months.

ICCC's SMR Rating (79) in the Medical Specialties industry is in the same range as CDTX (97) in the Biotechnology industry. This means that ICCC’s stock grew similarly to CDTX’s over the last 12 months.

CDTX's Price Growth Rating (34) in the Biotechnology industry is in the same range as ICCC (47) in the Medical Specialties industry. This means that CDTX’s stock grew similarly to ICCC’s over the last 12 months.

ICCC's P/E Growth Rating (39) in the Medical Specialties industry is somewhat better than the same rating for CDTX (100) in the Biotechnology industry. This means that ICCC’s stock grew somewhat faster than CDTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDTXICCC
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 15 days ago
85%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 23 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UEPEP72.360.11
+0.15%
Union Electric Co.
STLY3.90N/A
N/A
HG Holdings, Inc.
ALEGF7.65N/A
N/A
ALLEGRO EU SA
HTSUY6.80N/A
N/A
Hisamitsu Pharmaceutical Co., Ltd.
CCARF1.01-0.05
-4.72%
Colonial Coal International Corp

CDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDTX has been closely correlated with NBY. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDTX jumps, then NBY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDTX
1D Price
Change %
CDTX100%
-0.56%
NBY - CDTX
93%
Closely correlated
+17.54%
NCNA - CDTX
93%
Closely correlated
+2.01%
TAOX - CDTX
93%
Closely correlated
-3.38%
BPTSY - CDTX
92%
Closely correlated
N/A
KPRX - CDTX
90%
Closely correlated
+2.56%
More

ICCC and

Correlation & Price change

A.I.dvisor tells us that ICCC and UNCY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ICCC and UNCY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICCC
1D Price
Change %
ICCC100%
+5.60%
UNCY - ICCC
29%
Poorly correlated
-0.69%
CDTX - ICCC
24%
Poorly correlated
-0.56%
MYNDF - ICCC
24%
Poorly correlated
N/A
TRAW - ICCC
23%
Poorly correlated
+11.81%
JANX - ICCC
23%
Poorly correlated
+0.79%
More